Survival and prognostic association in stage IV colorectal cancer patients treated with chemotherapy in Bangladesh

Prognostic factors in colorectal cancer have lesser been evaluated in developing countries. This study aims to determine overall survival and prognostic factors for metastatic colorectal cancer patients who were non-operable and received chemotherapy. The study retrospectively investigated 67 inoper...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of clinical oncology 2021-04, Vol.51 (4), p.552-559
Main Authors: Shuayb, Md, Mehedi Hasan, Md, Hoque, Md Rashedul, Mushtaq Hussain, Qazi, Begum, Rabeya, Reza, Md Salim
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Bangladesh
Cohort Studies
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - pathology
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Neoplasm Staging
Prognosis
Proportional Hazards Models
Retrospective Studies
Survival Analysis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prognostic factors in colorectal cancer have lesser been evaluated in developing countries. This study aims to determine overall survival and prognostic factors for metastatic colorectal cancer patients who were non-operable and received chemotherapy. The study retrospectively investigated 67 inoperable metastatic colorectal cancer patients at Square Hospital, Bangladesh. The primary endpoint was overall survival, and the secondary endpoints were prognostic association with factors. Survival probabilities were calculated by non-parametric Kaplan-Meier method and compared by log-rank test. Univariate and multivariable Cox proportional hazard models were implemented to assess the prognostic association. Median survival of the entire cohort was 14 months (95% confidence interval: 11-25). In multivariable analysis, two prognostic factors were independently associated with survival: Karnofsky performance status and carcinoembryonic antigen. Patients with Karnofsky performance status 100 ng/ml, respectively, while comparing with carcinoembryonic antigen
ISSN:1465-3621
1465-3621
DOI:10.1093/jjco/hyaa228